pre-IPO PHARMA

COMPANY OVERVIEW

WUGEN INC. IS A BIOTECHNOLOGY COMPANY DEVELOPING A NOVEL CAR-T THERAPY PLATFORM INCLUDING AN “OFF-THE-SHELF” FRATRICIDE-RESISTANT CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES.


LOCATION

  • St. Louis, MO, USA
  • Brisbane, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://wugen.com


    CAREER WEBSITE

    https://wugen.com/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Aug 15, 2023

    Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)


    Jun 9, 2023

    Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress


    May 11, 2023

    Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress


    May 10, 2023

    Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors


    Apr 19, 2023

    Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023


    For More Press Releases


    Google Analytics Alternative